Ibrutinib for Blood Cancer Treatment

Ibrutinib, a breakthrough in blood cancer treatment, has transformed the management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By specifically targeting and inhibiting Bruton’s tyrosine kinase (BTK), a crucial protein for cancer cell survival, Ibrutinib disrupts the growth and spread of cancer cells.